Allogene Therapeutics, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: revenue, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
ALLO · Price history
Price at last available close
$1.30
−$0.32 (-19.75%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Allogene Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults.
How they make money
Allogene Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on funding research and development to advance a pipeline of allogeneic CAR T cell product candidates, with the goal of eventually commercializing these therapies for cancer and autoimmune diseases.
Products & services
The company develops allogeneic CAR T cell product candidates, including cema-cel and ALLO-316, which are engineered from healthy donor T cells for off-the-shelf use in patients.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Clinical trial patientsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Cellectis S.A. — The company maintains a license agreement to utilize Cellectis's TALEN-based gene-editing technology for the development of its allogeneic CAR T cell product candidates.Source
- Servier — The company holds an exclusive license agreement with Servier to commercialize certain CAR T products directed at specific targets.Source
Competitors
- Autologous CAR T therapy developers — Companies developing autologous CAR T cell therapies, which require patient-specific cell collection and processing.Source
Strengths
- Proprietary allogeneic CAR T platform technologySource
Sources
Company-specific research
Questions worth answering for ALLO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can ALLO fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does ALLO's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for ALLO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ALLO's current valuation?
- •What does the current corporate distress warning mean for the reliability or interpretation of ALLO's score?
Essential Investment Snapshot
Market Cap
$449.1M
P/E Ratio
-2.4
EPS
$-0.67
52-Week High
$4.46
52-Week Low
$1.04
Beta
0.48
Analyst Target
$6.42
Shares Outstanding
220.6M
Total Debt
$70.4M
Dividend
No current dividend
Liquidation Value / Share
$1.98
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ALLO
Detected from reported data — verify before acting.CRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingDebt service risk
Interest coverage is low (~-192.5x). Earnings may be strained to cover interest expense.
M&A headline · Sep 28, 2026
3,187,320 Shares of Allogene Therapeutics, Inc. $ALLO Acquired by Bank of America Corp DE — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on ALLO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary allogeneic CAR T platform technology.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party intellectual property and potential litigation (e.g., Factor Litigation).
- −Clinical trial failure and regulatory approval uncertainty.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$1.30
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -76.8%
Revenue changed sharply from 2023 to 2024. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $22K | $95K | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $12.4M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | -$12.4M | $22K | $95K | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $150.2M | $192.3M | $242.9M | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $56.8M | $65.2M | $71.7M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $194.6M | $273.2M | $327.8M | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$177.5M | -$243.3M | -$313.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$206.9M | -$273.2M | -$327.7M | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $1.1M | $181K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | -$190.9M | -$257.1M | -$327.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $443K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | -$190.9M | -$257.6M | -$327.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $-0.87 | $-1.32 | $-2.09 | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 329M | 221M | 195M | 157M | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 329M | 221M | 195M | 157M | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$4.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.13
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-11.2%
Cash Change
-26.2%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 43.5%. Cash declined 26.2%. Total debt declined 11.2%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
40
Smart Money
40
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
3,187,320 Shares of Allogene Therapeutics, Inc. $ALLO Acquired by Bank of America Corp DE
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Rumor Mill · ALLO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial